NovaBay Pharmaceuticals (NBY) - LifeTech Capital

More documents

Recommendations

Info

NovaBay’s Aganocide ® Technology What are NovaBay’s Aganocides ® and how do they kill pathogens? NovaBay’s Aganocides mimic the human body’s way of killing pathogens. When white blood cells (neutrophils) encounter foreign bacteria, they surround it and generate an oxidative burst process which destroys it. The oxidative burst creates hypochlorous acid (HOCI) molecules which are highly reactive and kill bacteria in seconds. NovaBay’s NeutroPhase NVC- 101 is a stable preparation of HOCI. The HOCI then reacts with taurine to create two antimicrobial molecules, N-chlorotaurine (NCT) and N,N,-dichlorotaurine (NNDCT). While both NCT and NNDCT are antimicrobial, NNDCT is significantly more effective. However, both are chemically unstable. NovaBay’s NVC-422 is a stable analog of NNDCT and we believe that NovaBay’s NVC-612 is a stable analog of NCT. www.LifeTechCapital.com December 7, 2010 BIOFILM-RELATED CHRONIC DISEASES Otitis media Legionnaire's disease Periodontitis Chronic wounds Myeloidosis Prostatitis Cystic fibrosis Necrotizing fasciitis Tonsillitis Dental caries Osteomyelitis Endocarditis Biliary tract infection Source: M. Ryder, PhD, MS, RN,”Catheter-Related Infections: It's All About Biofilm”; Topics in Advanced Practice Nursing eJournal. 2005;5(3) In addition, NovaBay’s Aganocides have already had successful in-vitro experiments demonstrating efficacy in destroying bacteria resident in biofilm as shown: NVC-422 In-vitro data shows high efficacy against well established biofilm grown on urinary tract catheters Source: NovaBay Pharmaceuticals Pathogen Killing Mechanism for HOCI, N-chlorotaurine & N,N-dichlorotaurine Source:NovaBay Pharmaceuticals NovaBay Pharmaceuticals (NBY) Page 6
www.LifeTechCapital.com December 7, 2010 How do NovaBay’s Aganocides ® Avoid Bacterial Resistance? Bacterial resistance to Aganocides is unlikely as Aganocides are analogs of molecules already used by the human immune system. The antimicrobial activity of NovaBay’s NVC-101 and Aganocides is based on active chlorine. Similar forms of chlorine have been used for over 100 years to purify drinking water supplies, having been first used in 1850 in London and in 1908 in the U.S., with no known chlorine resistance ever developing in humans. In contrast, the antibiotic methicillin was introduced in 1959 to treat infections caused by penicillin-resistant Staphylococcus aureus and by 1961 there were already reports in the U.K. of S. aureus isolates that had acquired resistance to methicillin. We believe the NovaBay’s Aganocide development strategy is valid considering their characteristics. Below is a table indicating the broad spectrum of activity for Aganocides seen in preclinical experiments: Pathogen AGANOCIDE ® Vancomycin Mupirocin Ciprofloxacin Gram Positive Bacteria Staphylococcus aureus � � � � Staphylococcus aureus (MRSA) � � � Enterococcus faecium (VRE) � Gram Negative Bacteria Escherichia coli � � Pseudomonas aeruginosa � � Acinetobacter calcoaceticus � � Yeast Candida albicans � Virus Adenovirus: 9 serotypes � Herpes Simplex Virus: 1 & 2 � Source: NovaBay Pharmaceuticals NVC- 422 MULTI-DRUG RESISTANT (MDR) BACTERIA Tetracycline Moxifloxacin PolymyxinB Ciprofloxacin Trimethoprim Acinetobacterjunii � � E. coli � � P. Aeruginosa � � S. pneumoniae � � S. epidermidis � � E. faecalis � � H. influenzae � � � � � S. aureus � � � � Source: NovaBay Pharmaceuticals NovaBay Pharmaceuticals (NBY) Page 7
Page 1 and 2: � Unlocking the Value of Science
Page 3 and 4: NovaBay Aganocide ® Development St
Page 5: Microbial Biofilm Infections www.Li
Page 9 and 10: www.LifeTechCapital.com December 7,
Page 23 and 24: Intellectual Property www.LifeTechC
Page 29: www.LifeTechCapital.com December 7,

NovaBay Pharmaceuticals (NBY) - LifeTech Capital

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?